Management of Pulmonary Arterial Hypertension.

ABSTRACT:

Purpose of review

This review focuses on the therapeutic management and individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food and Drug Administration-approved PAH-specific therapies and various interventional and surgical options for PAH.

Recent findings

The paradigm for the optimal management of PAH has shifted in recent years. Upfront combination therapy with an endothelin receptor antagonist and a phosphodiesterase 5 inhibitor is now widely accepted as standard of care. In addition, there is increasing emphasis on starting prostanoids early in order to delay time to clinical worsening. However, less is known regarding which prostanoid agent to initiate and the optimum time to do so. In order to facilitate shared decision-making, there is

SUBMITTER: Mayeux JD 

PROVIDER: S-EPMC7671829 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature